Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Account Payables (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Change in Account Payables data on record, last reported at $18.2 million in Q4 2025.

  • For Q4 2025, Change in Account Payables rose 1122.78% year-over-year to $18.2 million; the TTM value through Dec 2025 reached $18.2 million, up 1573.37%, while the annual FY2025 figure was $18.2 million, 1573.37% up from the prior year.
  • Change in Account Payables reached $18.2 million in Q4 2025 per APLS's latest filing, up from -$15.6 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $23.1 million in Q4 2022 and bottomed at -$15.6 million in Q3 2025.
  • Average Change in Account Payables over 5 years is $2.4 million, with a median of -$481000.0 recorded in 2021.
  • Peak YoY movement for Change in Account Payables: tumbled 8567.47% in 2022, then skyrocketed 1122.78% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $13.7 million in 2021, then surged by 68.8% to $23.1 million in 2022, then fell by 15.16% to $19.6 million in 2023, then tumbled by 92.42% to $1.5 million in 2024, then surged by 1122.78% to $18.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $18.2 million in Q4 2025, -$15.6 million in Q3 2025, and -$1.0 million in Q2 2025.